Article
Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.
International journal of hematology - 1 Jun 2023
Shirai Ryota, Osumi Tomoo, Keino Dai, Nakabayashi Kazuhiko, Uchiyama Toru, Sekiguchi Masahiro, Hiwatari Mitsuteru, Yoshida Masanori, Yoshida Kaoru, Yamada Yuji, Tomizawa Daisuke, Takae Seido, Kiyokawa Nobutaka, Matsumoto Kimikazu, Yoshioka Takako, Hata Kenichiro, Hori Toshinori, Suzuki Nao, Kato Motohiro
Abstract excerpt
Minimal residual disease (MRD) is usually defined as the small number of cancer cells that remain in the body after treatment. The clinical significance of MRD kinetics is well recognized in treatment of hematologic malignancies, particularly acute lymphoblastic leukemia (ALL). Real time quantitative PCR targeting immunoglobulin (Ig) or T-cell receptor (TCR) rearrangement (PCR-MRD), as well as multiparametric...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.